TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03942185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy
Description: Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Chinese Herbal Medicine according with syndrome differentiation therapy
Description: Oral Chinese Herbal Medicine according with syndrome differentiation therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy
Description: Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
Study: NCT01476098

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SB-705498 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: SB-705498 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SB-705498
Description: 400 or 600mg oral SB-705498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB-705498
Description: 400 or 600mg oral SB-705498
Study: NCT02183844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Weight Intervention
Description: Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
Study: NCT04660591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: femoral stem in hip arthroplasty
Description: using lateral approach to the hip we will compare the effect of femoral stem length on the oncological and functional outcomes in patients with proximal femoral metastasis.hip arthroplasty is a surgical procedure that involves changing the head of the femur (the ball) with or without replacing the articular surface of the acetabulum (the socket ).and replacing it with metal head based on a stem covered with cement to fix it to the bone of the femur.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: femoral stem in hip arthroplasty
Description: using lateral approach to the hip we will compare the effect of femoral stem length on the oncological and functional outcomes in patients with proximal femoral metastasis.hip arthroplasty is a surgical procedure that involves changing the head of the femur (the ball) with or without replacing the articular surface of the acetabulum (the socket ).and replacing it with metal head based on a stem covered with cement to fix it to the bone of the femur.
Study: NCT03180177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: HIPEC is performed as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 24h after laparoscopic exploration or Interval debulking surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The second HIPEC regimens are cisplatin 75 mg/m\^2, 43°C, 90min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interval debulking surgery
Description: Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interval debulking surgery
Description: Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group.
Study: NCT03510494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented physical education program
Description: Augmented physical education program
Study: NCT00555594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (Avastin)
Description: One dose of 0.1cc of subconjunctival Bevacizumab was applied

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (Avastin)
Description: One dose of 0.1cc of subconjunctival Bevacizumab was applied
Study: NCT01344954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Administered intravenously over 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Administered orally as a capsule once a day for 35 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: Administered intravenously over 10 minutes
Study: NCT00816478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galactose
Description: Oral galactose, 0.2 g/kg/dose twice daily for 28 days
Study: NCT03316820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study treatment with water after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study treatment with water after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study treatment with water after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study treatment with water after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study treatment with water after food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study treatment with water after food
Study: NCT04589871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping technique
Description: Fixmull stretch and Leukotape (rigid tape) were used in taping to guide the patellar trajectory orientation while performing the movement. Individuals were asked to lay down in supine position with knee in a slightly bent position. Fixomull stretch was used as an adhesive pre-wrap to protect the skin and provide some of the checking force. The main check strap was provided by stripes of rigid tape (Leukotape). The knee cap was taped, started on the outer aspect of the knee cap and pulled inwards. Finished at the back of the inside of the knee. Two further pieces of tape (Fixomull Stretch and Leukotape) applied distal to the patella unloaded the infrapatellar fat pad.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A supervised exercise protocol
Description: Quadriceps Strengthening; Terminal knee extension; Ball kicking; Strengthening of Vastus Medialis;
Study: NCT03316820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study treatment with water after food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Study treatment with water after food
Study: NCT01254240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA / UVB phototherapy
Description: UVA / UVB phototherapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVB phototherapy
Description: UVB phototherapy
Study: NCT04589871

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A supervised exercise protocol
Description: Quadriceps Strengthening; Terminal knee extension; Ball kicking; Strengthening of Vastus Medialis;
Study: NCT00754585

Intervention type: DEVICE
Intervention: Logic Back Grahl Duo Back Model DB11-01
Description: The device is placed against the back rest of a chair. The tension of the straps are adjusted for each participant to obtain the ENP.
Study: NCT00142181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.
Study: NCT02592993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay device
Description: The PicoWay base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier.
Study: NCT03108456

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orbital Atherectomy
Description: Vessel preparation with Orbital Atherectomy followed by balloon pre-dilatation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon
Description: Vessel preparation with conventional and/or specialty balloons
Study: NCT00950794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol(SN408D)
Description: Salmeterol(SN408D)：long-acting Beta2-agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hokunalin (tulobuterol) tape
Description: Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
Study: NCT02138084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir
Study: NCT01296789

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue perfusion guided protocol
Description: A tissue perfusion guided protocol is used to guide hemodynamic therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care
Study: NCT03254446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC150094
Description: TRC150094 Tablet 45 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Tablet
Study: NCT01482026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADHD Rating Scale-IV
Description: ADHD Rating Scale-IV test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADHD Rating Scale-IV
Description: ADHD Rating Scale-IV test
Study: NCT00381615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-CRM
Description: MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-CRM
Description: MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-CRM
Description: MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-Hib
Description: MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-Hib
Description: MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-Hib
Description: MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-Hib
Description: MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
Study: NCT01654926

Intervention type: PROCEDURE
Intervention: blood ultrafiltration
Study: NCT01135134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: The study drug is MFNS (50 μg spray device) and the dose will be:~* 5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MF Placebo nasal spray and administration will be as follows:~* 5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~* 12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks
Study: NCT04073121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminor DCB and Angiolite DES
Description: Patient to undergo angioplasty with Luminor DCB and Angiolite DES
Study: NCT01059409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meniscal Allograft
Description: Meniscal Allograft
Study: NCT01546558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1000 mg bid on Days 1-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine 500 mg bid on Days 6-10
Study: NCT03898726

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopical l cuff closure
Description: closure of vaginal cuff following hysterectomy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopical l cuff closure
Description: closure of vaginal cuff following hysterectomy
Study: NCT01496235

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dark chocolate
Description: Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White chocolate
Description: Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
Study: NCT00381615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR
Description: IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
Study: NCT02595073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS
Description: Active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment
Study: NCT00134303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is used.
Study: NCT00631358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxidex
Description: Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
Study: NCT02046889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bicycle Training Intervention
Study: NCT00151580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 18 months of oral ribavirin maintenance treatment
Study: NCT00631358

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No treatment
Description: Healthy normal control group receiving no treatment
Study: NCT00151580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 18 months oral placebo treatment
Study: NCT02512640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volume-controlled ventilation
Description: a tidal volume of 8 ml/kg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure-controlled ventilation
Description: a peak airway pressure to maintain a tidal volume of 8 ml/kg
Study: NCT02647775

Intervention type: PROCEDURE
Group type: OTHER
Intervention: multi-port VATS
Description: Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: single-port VATS
Description: Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
Study: NCT00568412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zarzenda
Description: Topical cream, applied twice daily for three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel
Description: 1% cream, applied topically twice daily for three weeks
Study: NCT01737827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: INC280 was administered orally on a continuous twice a day (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle. INC280 was initially supplied as hard gelatin capsules and subsequently also as film-coated tablets.
Study: NCT03695458

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy
Description: The Photobiomodulation Therapy will be applied 3 minutes after MVC test in 6 points of the quadriceps muscle (2 points in vastus lateralis, 2 in rectus femoris and 2 in vastus medialis).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: The Photobiomodulation Therapy will be applied 3 minutes after MVC test in 6 points of the quadriceps muscle (2 points in vastus lateralis, 2 in rectus femoris and 2 in vastus medialis).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: The Photobiomodulation Therapy will be applied 3 minutes after MVC test in 6 points of the quadriceps muscle (2 points in vastus lateralis, 2 in rectus femoris and 2 in vastus medialis).
Study: NCT02141022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasticity-based computerized cognitive remediation program

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gileyna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gileyna
Study: NCT04224207

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wharton's jelly derived mesenchymal stem cell
Description: The mesenchymal cells that were used in this study were isolated from Wharton's jelly of the umbilical cord that was collected allogenicly from a single donor with the mother's consent. All cell preparation and cultivation procedures were conducted in a current Good Manufacturing Practice (cGMP) accredited laboratory (Onkim Stem Cell Technologies, Turkey).Cells were solubilized from cryopreservation before being made ready for injection. Average cell viability for each treatment was over 90.0% and each patient received cell numbers between 2-6x106 in a 1.5 ml saline solution .

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wharton's jelly derived mesenchymal stem cell
Description: The mesenchymal cells that were used in this study were isolated from Wharton's jelly of the umbilical cord that was collected allogenicly from a single donor with the mother's consent. All cell preparation and cultivation procedures were conducted in a current Good Manufacturing Practice (cGMP) accredited laboratory (Onkim Stem Cell Technologies, Turkey).Cells were solubilized from cryopreservation before being made ready for injection. Average cell viability for each treatment was over 90.0% and each patient received cell numbers between 2-6x106 in a 1.5 ml saline solution .
Study: NCT01915160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTF-CBT
Description: Standard treatment with the edition of in-treatment/session iPad activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TF-CBT
Description: Treatment as usual.
Study: NCT04353128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 2mg
Description: 2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Identically looking placebo tablets P.O. before bedtime for 12 weeks
Study: NCT01007357

Intervention type: DEVICE
Group type: OTHER
Intervention: Body MR imaging
Description: Body MR imaging will be performed to optimize sequences